Replies to post #9761 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Form what I see, your link does not "stipulate" to what I highlighted in my last post.

Algernon Pharmaceuticals Inc.’s NP-120 (ifenprodil), which is expected to begin a 462-patient open-label phase II/III study in July, with expected completion in January 2022.

I personally haven't gotten around to reviewing the Kiss of Death webcast, but I will, and I will likely opine on the above details based on what came straight from the CEO's mouth.


/////AMG